ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v635-v636 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v636 |
|---|---|
| container_issue | |
| container_start_page | v635 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Morgensztern, D. Ong, T.J. Dols, M. Cobo Aix, S. Ponce Postmus, P.E. Lewanski, C. Bennouna, J. Fischer, J.R. Vidal, O.J. Stewart, D.J. Fasola, G. Ardizoni, A. Weaver, J. Wolfsteiner, M. Talbot, D. Govindan, R. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx440.051 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx440_051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420391511</els_id><sourcerecordid>S0923753420391511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1851-375f618824996afe0b9d6337ccbd06effedeb6e0301f451bf0c66de36d01f9e3</originalsourceid><addsrcrecordid>eNp9kN1OAjEQhRujiYg-gHe9hJBCS3fLVq9w_U0ImIjXm247qzX7Q9oF4Rl8aUvWa29mMmdyJnM-hK4ZHTMq-UTVdVPrSWX2UUTHNGYnqMdiIUlCI3aKelROOZnFPDpHF95_UUqFnMoe-pnfrd6X9-PpYnSDa5WTjdKlbdUeSjw4zq9DPJoQnKYkSgRuHDZbt1PltlI5tjXeONjZZuvLA24dqBYM3qjWQt16_G3bT6zMTtU6yOE_4itVllhDKOW2_sD6uHJ4sHxLF-nwEp0VqvRw9df7aP34sE6fyWL19JLOF0SzJGaEz-JCsCSZRlIKVQDNpRGcz7TODRVQFGAgF0A5ZUUUs7ygWggDXJggSOB9xLqz2jXeOyiyjbOVcoeM0ewIM-tgZh3MLMAMntvOA-GvnQWXeR1ChlzWgW4z09h_3L_itn5Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Morgensztern, D. ; Ong, T.J. ; Dols, M. Cobo ; Aix, S. Ponce ; Postmus, P.E. ; Lewanski, C. ; Bennouna, J. ; Fischer, J.R. ; Vidal, O.J. ; Stewart, D.J. ; Fasola, G. ; Ardizoni, A. ; Weaver, J. ; Wolfsteiner, M. ; Talbot, D. ; Govindan, R.</creator><creatorcontrib>Morgensztern, D. ; Ong, T.J. ; Dols, M. Cobo ; Aix, S. Ponce ; Postmus, P.E. ; Lewanski, C. ; Bennouna, J. ; Fischer, J.R. ; Vidal, O.J. ; Stewart, D.J. ; Fasola, G. ; Ardizoni, A. ; Weaver, J. ; Wolfsteiner, M. ; Talbot, D. ; Govindan, R.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx440.051</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v635-v636</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1851-375f618824996afe0b9d6337ccbd06effedeb6e0301f451bf0c66de36d01f9e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Morgensztern, D.</creatorcontrib><creatorcontrib>Ong, T.J.</creatorcontrib><creatorcontrib>Dols, M. Cobo</creatorcontrib><creatorcontrib>Aix, S. Ponce</creatorcontrib><creatorcontrib>Postmus, P.E.</creatorcontrib><creatorcontrib>Lewanski, C.</creatorcontrib><creatorcontrib>Bennouna, J.</creatorcontrib><creatorcontrib>Fischer, J.R.</creatorcontrib><creatorcontrib>Vidal, O.J.</creatorcontrib><creatorcontrib>Stewart, D.J.</creatorcontrib><creatorcontrib>Fasola, G.</creatorcontrib><creatorcontrib>Ardizoni, A.</creatorcontrib><creatorcontrib>Weaver, J.</creatorcontrib><creatorcontrib>Wolfsteiner, M.</creatorcontrib><creatorcontrib>Talbot, D.</creatorcontrib><creatorcontrib>Govindan, R.</creatorcontrib><title>ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kN1OAjEQhRujiYg-gHe9hJBCS3fLVq9w_U0ImIjXm247qzX7Q9oF4Rl8aUvWa29mMmdyJnM-hK4ZHTMq-UTVdVPrSWX2UUTHNGYnqMdiIUlCI3aKelROOZnFPDpHF95_UUqFnMoe-pnfrd6X9-PpYnSDa5WTjdKlbdUeSjw4zq9DPJoQnKYkSgRuHDZbt1PltlI5tjXeONjZZuvLA24dqBYM3qjWQt16_G3bT6zMTtU6yOE_4itVllhDKOW2_sD6uHJ4sHxLF-nwEp0VqvRw9df7aP34sE6fyWL19JLOF0SzJGaEz-JCsCSZRlIKVQDNpRGcz7TODRVQFGAgF0A5ZUUUs7ygWggDXJggSOB9xLqz2jXeOyiyjbOVcoeM0ewIM-tgZh3MLMAMntvOA-GvnQWXeR1ChlzWgW4z09h_3L_itn5Z</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Morgensztern, D.</creator><creator>Ong, T.J.</creator><creator>Dols, M. Cobo</creator><creator>Aix, S. Ponce</creator><creator>Postmus, P.E.</creator><creator>Lewanski, C.</creator><creator>Bennouna, J.</creator><creator>Fischer, J.R.</creator><creator>Vidal, O.J.</creator><creator>Stewart, D.J.</creator><creator>Fasola, G.</creator><creator>Ardizoni, A.</creator><creator>Weaver, J.</creator><creator>Wolfsteiner, M.</creator><creator>Talbot, D.</creator><creator>Govindan, R.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)</title><author>Morgensztern, D. ; Ong, T.J. ; Dols, M. Cobo ; Aix, S. Ponce ; Postmus, P.E. ; Lewanski, C. ; Bennouna, J. ; Fischer, J.R. ; Vidal, O.J. ; Stewart, D.J. ; Fasola, G. ; Ardizoni, A. ; Weaver, J. ; Wolfsteiner, M. ; Talbot, D. ; Govindan, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1851-375f618824996afe0b9d6337ccbd06effedeb6e0301f451bf0c66de36d01f9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morgensztern, D.</creatorcontrib><creatorcontrib>Ong, T.J.</creatorcontrib><creatorcontrib>Dols, M. Cobo</creatorcontrib><creatorcontrib>Aix, S. Ponce</creatorcontrib><creatorcontrib>Postmus, P.E.</creatorcontrib><creatorcontrib>Lewanski, C.</creatorcontrib><creatorcontrib>Bennouna, J.</creatorcontrib><creatorcontrib>Fischer, J.R.</creatorcontrib><creatorcontrib>Vidal, O.J.</creatorcontrib><creatorcontrib>Stewart, D.J.</creatorcontrib><creatorcontrib>Fasola, G.</creatorcontrib><creatorcontrib>Ardizoni, A.</creatorcontrib><creatorcontrib>Weaver, J.</creatorcontrib><creatorcontrib>Wolfsteiner, M.</creatorcontrib><creatorcontrib>Talbot, D.</creatorcontrib><creatorcontrib>Govindan, R.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morgensztern, D.</au><au>Ong, T.J.</au><au>Dols, M. Cobo</au><au>Aix, S. Ponce</au><au>Postmus, P.E.</au><au>Lewanski, C.</au><au>Bennouna, J.</au><au>Fischer, J.R.</au><au>Vidal, O.J.</au><au>Stewart, D.J.</au><au>Fasola, G.</au><au>Ardizoni, A.</au><au>Weaver, J.</au><au>Wolfsteiner, M.</au><au>Talbot, D.</au><au>Govindan, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v635</spage><epage>v636</epage><pages>v635-v636</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx440.051</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v635-v636 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx440_051 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A10%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ABOUND.2L+:%20nab-paclitaxel%20(nab-P)%20+/-%20CC-486%20or%20durvalumab%20in%20previously%20treated%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20(NSCLC)&rft.jtitle=Annals%20of%20oncology&rft.au=Morgensztern,%20D.&rft.date=2017-09&rft.volume=28&rft.spage=v635&rft.epage=v636&rft.pages=v635-v636&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx440.051&rft_dat=%3Celsevier_cross%3ES0923753420391511%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420391511&rfr_iscdi=true |